litlas
ログインアカウント作成

Kristian Reich

1991–2025 年に発表

220
論文数
36,393
被引用数
104
h 指数
216
i10 指数

被引用数

Kristian Reich の年別被引用数1964 年: 被引用 1 件1984 年: 被引用 1 件1991 年: 被引用 2 件1992 年: 被引用 2 件1993 年: 被引用 1 件1994 年: 被引用 9 件1995 年: 被引用 4 件1996 年: 被引用 7 件1997 年: 被引用 2 件1998 年: 被引用 7 件1999 年: 被引用 4 件2000 年: 被引用 6 件2001 年: 被引用 11 件2002 年: 被引用 18 件2003 年: 被引用 20 件2004 年: 被引用 20 件2005 年: 被引用 32 件2006 年: 被引用 29 件2007 年: 被引用 58 件2008 年: 被引用 58 件2009 年: 被引用 118 件2010 年: 被引用 121 件2011 年: 被引用 143 件2012 年: 被引用 159 件2013 年: 被引用 184 件2014 年: 被引用 192 件2015 年: 被引用 235 件2016 年: 被引用 338 件2017 年: 被引用 491 件2018 年: 被引用 513 件2019 年: 被引用 1,421 件2020 年: 被引用 1,702 件2021 年: 被引用 1,722 件2022 年: 被引用 1,396 件2023 年: 被引用 1,336 件2024 年: 被引用 1,692 件2025 年: 被引用 907 件2026 年: 被引用 5 件1965〜1983 年は被引用が無いため表示していません1985〜1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,254 件、この内訳の 19.4%ドイツ: 引用元論文 1,141 件、この内訳の 9.8%イギリス: 引用元論文 863 件、この内訳の 7.4%イタリア: 引用元論文 705 件、この内訳の 6.1%カナダ: 引用元論文 696 件、この内訳の 6%中国: 引用元論文 629 件、この内訳の 5.4%フランス: 引用元論文 509 件、この内訳の 4.4%日本: 引用元論文 447 件、この内訳の 3.9%スペイン: 引用元論文 435 件、この内訳の 3.8%スイス: 引用元論文 408 件、この内訳の 3.5%オランダ: 引用元論文 355 件、この内訳の 3.1%デンマーク: 引用元論文 301 件、この内訳の 2.6%
0%19.4%その他 24.6%

機関

分野

  • Immunology and Microbiology46.5%
  • Medicine44.1%
  • Biochemistry, Genetics and Molecular Biology6%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Neuroscience0.6%
  • Health Professions0.3%
  • その他1.7%

トピック

  • Psoriasis: Treatment and Pathogenesis19.6%
  • Dermatology and Skin Diseases13.7%
  • Spondyloarthritis Studies and Treatments8.5%
  • Asthma and respiratory diseases3.9%
  • Rheumatoid Arthritis Research and Therapies3.5%
  • Allergic Rhinitis and Sensitization3.3%
  • その他47.5%

共著者

全論文

検索で開く
  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

    著者: Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, C.E.M. Griffiths, Kim Papp, L. Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen‐Fang Tsai, Norman Wasel, Stephen K. Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, C. Papavassilis - New England Journal of Medicine 2014 被引用: 1,964

  2. Bimekizumab versus Secukinumab in Plaque Psoriasis

    著者: Kristian Reich, Richard B. Warren, Mark Lebwohl, Melinda Gooderham, Bruce Strober, Richard G. Langley, C. Paul, Dirk De Cuyper, Veerle Vanvoorden, Cynthia Madden, Christopher L. Cioffi, Luke Peterson, Andrew Blauvelt - New England Journal of Medicine 2021 被引用: 400

  3. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Kristian Reich, Henrique D. Teixeira, Marjolein de Bruin‐Weller, Thomas Bieber, Weily Soong, Kenji Kabashima, Thomas Werfel, Jiewei Zeng, Xiaohong Huang, Xiaofei Hu, Barbara A. Hendrickson, Barry Ladizinski, Alvina D. Chu, Jonathan I. Silverberg - The Lancet 2021 被引用: 389

  4. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

    著者: Kristian Reich, April W. Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, B. Randazzo, Shu Li, Yaung‐Kaung Shen, Kenneth B. Gordon - Journal of the American Academy of Dermatology 2017 被引用: 731

  5. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    著者: Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi - New England Journal of Medicine 2016 被引用: 838

  6. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

    著者: Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P. Rice, Hwanhee Hong, Norito Katoh, Fernando Valenzuela, Marco DiBonaventura, Tamara A. Bratt, Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernán Valdez, Urs Kerkmann - The Lancet 2022 被引用: 237

  7. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

    著者: Emma Guttman‐Yassky, Eric L. Simpson, Kristian Reich, Kenji Kabashima, Ken Igawa, Tetsuya Suzuki, Hirotaka Mano, Takeshi Matsui, Ehsanollah Esfandiari, Masutaka Furue - The Lancet 2022 被引用: 174

  8. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    著者: Kristian Reich, Kim Papp, Andrew Blauvelt, Stephen K. Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, N. Cichanowitz, Qing Li, Kenneth Liu, Carmen La Rosa, Stuart Green, Alexa B. Kimball - The Lancet 2017 被引用: 556

  9. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

    著者: Kristian Reich, April W. Armstrong, Richard G. Langley, Susan Flavin, B. Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt - The Lancet 2019 被引用: 376

  10. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

    著者: Kristian Reich, Kim Papp, Andrew Blauvelt, Richard G. Langley, April W. Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, Veerle Vanvoorden, Mark Lebwohl - The Lancet 2021 被引用: 297

  11. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

    著者: Kenneth B. Gordon, Peter Foley, James G. Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher L. Cioffi, Andrew Blauvelt - The Lancet 2021 被引用: 284

  12. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

    著者: Marjolein de Bruin‐Weller, Diamant Thaçi, Catherine Smith, Kristian Reich, Michael J. Cork, Allen Radin, Q. Zhang, Bolanle Akinlade, A. Gadkari, Laurent Eckert, Thomas Hultsch, Z. Chen, Gianluca Pirozzi, Neil M.H. Graham, Brad Shumel - British Journal of Dermatology 2017 被引用: 475

  13. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    著者: Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G. Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, C.E.M. Griffiths - Journal of the American Academy of Dermatology 2015 被引用: 669

  14. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

    著者: Alexander Nast, Catherine Smith, Phyllis I. Spuls, G. Avila Valle, Zsuzsanna Bata‐Csörgõ, Hugo Boonen, E.M.G.J. de Jong, I. García‐Doval, Paolo Gisondi, Diljit Kaur‐Knudsen, Satveer K. Mahil, Tarja Mälkönen, Julia‐Tatjana Maul, S. Mburu, Ulrich Mrowietz, Kristian Reich, Éva Remenyik, Kirsten Rønholt, Paul Sator, Marcus Schmitt‐Egenolf, Mariusz Sikora, Klaus Strömer, Olav Sundnes, David Trigos, G. E. van der Kraaij, Nikhil Yawalkar, Corinna Dressler - Journal of the European Academy of Dermatology and Venereology 2020 被引用: 389

  15. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

    著者: Emma Guttman‐Yassky, Diamant Thaçi, Aileen L. Pangan, Hwanhee Hong, Kim Papp, Kristian Reich, Lisa A. Beck, Mohamed‐Eslam F. Mohamed, Ahmed A. Othman, J. Anderson, Yihua Gu, Henrique D. Teixeira, Jonathan I. Silverberg - Journal of Allergy and Clinical Immunology 2019 被引用: 357

  16. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

    著者: Mette Deleuran, Diamant Thaçi, Lisa A. Beck, Marjolein de Bruin‐Weller, Andrew Blauvelt, Seth Forman, Robert Bissonnette, Kristian Reich, Weily Soong, Iftikhar Hussaın, Peter Foley, Michihiro Hide, Jean‐David Bouaziz, Joel M. Gelfand, Lawrence Sher, Marie L. A. Schuttelaar, Chen Wang, Zhen Chen, Bolanle Akinlade, Abhijit Gadkari, Laurent Eckert, John D. Davis, Manoj Rajadhyaksha, Heribert Staudinger, Neil M.H. Graham, Gianluca Pirozzi, Marius Ardeleanu - Journal of the American Academy of Dermatology 2019 被引用: 256

  17. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

    著者: Eric L. Simpson, Melinda Gooderham, Andreas Wollenberg, Stephan Weidinger, April W. Armstrong, Jennifer Soung, Silvia Mariel Ferrucci, Renata Gontijo Lima, Michael M. Witte, Wen Xu, Hany Elmaraghy, Chitra R Natalie, Evangeline Pierce, Andrew Blauvelt, ADhere Investigators, Abel Jarell, Neil S. Sadick, Howard Sofen, Paul W Wallace, Jose M Carpio, David Greenstein, Angela Moore, Jose M Mendez, Scott Guenthner, Wendy McFalda, Vivian Laquer, Seth Forman, Todd Schlesinger, Andrew Blauvelt, Jeffrey Crowley, Ricardo Tan, Francis J Averill, Rosalyn Elizabeth George, Eddie Armas, Benjamin Lockshin, Jennifer Soung, Walter K. Nahm, Alison Ehrlich, Sunil Dhawan, Eric L. Simpson, Steve Sitar, Jerry Bagel, Phoebe Rich, Bruce Torkan, David F Fivenson, Jamie Weisman, Melody Lynn Stone, April W. Armstrong, Mirwais Saifi, Brad Glick, Melinda Gooderham, Isaiah Day, Lorne Albrecht, Marni Wiseman, David Gratton, Chi-ho Hong, Bernadetta Majorek‐Olechowska, Adam Reich, Beata Kręcisz, Irena Walecka-Herniczek, Jolanta Węgłowska, Beata Bergler‐Czop, Boguslawa Cimoszko, Kamila Padlewska, Maria Czubek, Andreas Pinter, Kristian Reich, Thomas Wildfeuer, Roland Aschoff - JAMA Dermatology 2023 被引用: 143

  18. Bimekizumab versus Adalimumab in Plaque Psoriasis

    著者: Richard B. Warren, Andrew Blauvelt, Jerry Bagel, Kim Papp, Paul S. Yamauchi, April W. Armstrong, Richard G. Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher L. Cioffi, Luke Peterson, Nancy Cross, Kristian Reich - New England Journal of Medicine 2021 被引用: 238

  19. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

    著者: Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey Crowley, Caitriona Ryan, James G. Krueger, Tsen‐Fang Tsai, Mary Flack, Yihua Gu, David Williams, Elizabeth H. Thompson, C. Paul - The Lancet 2019 被引用: 298

  20. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

    著者: Kristian Reich, Kenji Kabashima, Ketty Peris, Jonathan I. Silverberg, Lawrence F. Eichenfield, Thomas Bieber, Aleksandra Kaszuba, Jill Kolodsick, Fan Emily Yang, Margaret Gamalo, Dennis Brinker, Amy M. DeLozier, Jonathan Janes, Fabio P. Nunes, Jacob P. Thyssen, Eric L. Simpson - JAMA Dermatology 2020 被引用: 279

  21. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials

    著者: Eric L. Simpson, J.‐P. Lacour, Lynda Spelman, Ricardo Galimberti, Lawrence F. Eichenfield, Robert Bissonnette, Brett King, Jacob P. Thyssen, Jonathan I. Silverberg, Thomas Bieber, Kenji Kabashima, Yuichiro Tsunemi, Antonio Costanzo, Emma Guttman‐Yassky, Lisa A. Beck, Jonathan Janes, Amy M. DeLozier, Margaret Gamalo, Dennis Brinker, T. Cardillo, Fabio P. Nunes, Amy S. Paller, Andreas Wollenberg, Kristian Reich - British Journal of Dermatology 2020 被引用: 379

  22. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

    著者: Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich - The Lancet 2008 被引用: 1,350

  23. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    著者: C.E.M. Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, C. Paul, Alan Menter, Gregory S. Cameron, J. Erickson, Lu Zhang, Roberta J. Secrest, Susan Ball, Daniel Braun, Olawale Osuntokun, Michael Heffernan, Brian J. Nickoloff, Kim Papp - The Lancet 2015 被引用: 831

  24. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks

    著者: Esther von Stebut, Kristian Reich, Diamant Thaçi, Wolfgang Köenig, Andreas Pinter, Andreas Körber, Tienush Rassaf, Ari Waisman, Venkatesh Mani, Denise P. Yates, Jennifer Frueh, Christian Sieder, Nima Melzer, Nehal N. Mehta, Tommaso Gori - Journal of Investigative Dermatology 2018 被引用: 223